APA (7th ed.) Citation

JM, F., GF, S., JM, W., AM, B., G, F., MG, D. P., . . . RM, S. (2025). Phase 1 first-in-human dose-expansion study of the oral SF3B1 modulator H3B‑8800 in lower-risk myelodysplastic syndrome. Leukemia research, 156, 107735. https://doi.org/10.1016/j.leukres.2025.107735

Chicago Style (17th ed.) Citation

JM, Foran, et al. "Phase 1 First-in-human Dose-expansion Study of the Oral SF3B1 Modulator H3B‑8800 in Lower-risk Myelodysplastic Syndrome." Leukemia Research 156 (2025): 107735. https://doi.org/10.1016/j.leukres.2025.107735.

MLA (9th ed.) Citation

JM, Foran, et al. "Phase 1 First-in-human Dose-expansion Study of the Oral SF3B1 Modulator H3B‑8800 in Lower-risk Myelodysplastic Syndrome." Leukemia Research, vol. 156, 2025, p. 107735, https://doi.org/10.1016/j.leukres.2025.107735.